Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295095 | 1.00 | MAOB (0.48) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL8577158 | 0.82 | MAOB (0.48) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL1289345 | 0.81 | MAOB (0.52) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL1396038 | 0.79 | MAOB (0.41) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL3295725 | 0.78 | TRPA1 (0.46) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL8714626 | 0.78 | TDP1 (0.43) | TRPA1SIGMAR1CYP2D6TSHRKMT2A | |
| SCHEMBL8174260 | 0.77 | MAOB (0.48) | MAOBTRPA1CA1CA2ARG2 | |
| SCHEMBL794180 | 0.76 | MAOB (0.46) | MAOBTRPA1TAAR1SLC6A2SIGMAR1 | |
| SCHEMBL5680524 | 0.76 | MAOB (0.46) | MAOBTRPA1TAAR1SLC6A2SIGMAR1 | |
| SCHEMBL11098509 | 0.76 | SIGMAR1 (0.50) | MAOBTRPA1TAAR1SLC6A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203742-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SURLERAUX DOMINIQUE LOIS NESTO | 2009-08-13 | — | — | US | disclosed |
| US-7199148-B2 | Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD (IE) | 2007-04-03 | — | — | US | disclosed |
| US-20060058368-A1 | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2006-03-16 | — | — | US | disclosed |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203742-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS2 | MAOB 2623/4885TRPA1 1449/4885CA1 3407/4885 |
| US-20060058368-A1 | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors | CYP2S1, CYP2C8, CYP8B1 | MAOB 399/4885TRPA1 3896/4885CA1 1831/4885 |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | PRSS1, SPINT2, TMPRSS2 | MAOB 2586/4885TRPA1 1444/4885CA1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.